α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients

Objective: Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imat...

Descripción completa

Detalles Bibliográficos
Autores principales: Etienne, Gabriel, Dupouy, Maryse, Costaglioli, Patricia, Chollet, Claudine, Lagarde, Valérie, Pasquet, Jean-Max, Reiffers, Josy, Garbay, Bertrand, Mahon, François-Xavier, Turcq, Béatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2011
Materias:
Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825081/
https://www.ncbi.nlm.nih.gov/pubmed/21734341
http://dx.doi.org/10.3233/DMA-2011-0777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825081/
https://www.ncbi.nlm.nih.gov/pubmed/21734341
http://dx.doi.org/10.3233/DMA-2011-0777

Ejemplares similares